{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:24:04Z","timestamp":1791278644070,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T00:00:00Z","timestamp":1372723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/nrneph.2013.125","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T13:13:05Z","timestamp":1372770785000},"page":"443-458","source":"Crossref","is-referenced-by-count":103,"title":["Treatment of idiopathic membranous nephropathy"],"prefix":"10.1038","volume":"9","author":[{"given":"Julia M.","family":"Hofstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,2]]},"reference":[{"key":"BFnrneph2013125_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/ndt\/gfp665","volume":"25","author":"EP McQuarrie","year":"2010","unstructured":"McQuarrie, E. P., Mackinnon, B., Stewart, G. A., Geddes, C. C. Membranous nephropathy remains the commonest primary cause of nephrotic syndrome in a northern European Caucasian population. Nephrol. Dial. Transplant. 25, 1009\u20131010 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl. 1","key":"BFnrneph2013125_CR2","first-page":"64","volume":"7","author":"RJ Glassock","year":"1992","unstructured":"Glassock, R. J. Secondary membranous glomerulonephritis. Nephrol. Dial. Transplant. 7 (Suppl. 1) 64\u201371 (1992).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR3","first-page":"313","volume":"33","author":"DB Jones","year":"1957","unstructured":"Jones, D. B. Nephrotic glomerulonephritis. Am. J. Pathol. 33, 313\u2013329 (1957).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph2013125_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3181\/00379727-100-24736","volume":"100","author":"W Heymann","year":"1959","unstructured":"Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G., Hunter, J. L. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660\u2013664 (1959).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrneph2013125_CR5","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","volume":"79","author":"D Kerjaschki","year":"1982","unstructured":"Kerjaschki, D., Farquhar, M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA 79, 5557\u20135561 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2013125_CR6","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053\u20132060 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H. et al. M type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M., Beck, L. H. Jr, Beck, D. M., Wetzels, J. F. & Salant, D. J. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286\u20131291 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137\u20131143 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","volume":"364","author":"HC Stanescu","year":"2011","unstructured":"Stanescu, H. C. et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 364, 616\u2013626 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR11","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2, 186\u2013197 (2012)."},{"key":"BFnrneph2013125_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/ndt\/gfr371","volume":"27","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. & Wetzels, J. F. Management of patients with membranous nephropathy. Nephrol. Dial. Transplant. 27, 6\u20139 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ndt\/gfg616","volume":"19","author":"H Ohtani","year":"2004","unstructured":"Ohtani, H. et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol. Dial. Transplant. 19, 574\u2013579 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR14","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ndt\/gfr534","volume":"27","author":"Z Qu","year":"2012","unstructured":"Qu, Z. et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol. Dial. Transplant. 27, 1931\u20131937 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR15","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2215\/CJN.04800511","volume":"7","author":"YS Song","year":"2012","unstructured":"Song, Y. S., Min, K. W., Kim, J. H., Kim, G. H. & Park, M. H. Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis. Clin. J. Am. Soc. Nephrol. 7, 1947\u20131955 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR16","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","volume":"70","author":"C Lefaucheur","year":"2006","unstructured":"Lefaucheur, C. et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 70, 1510\u20131517 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR17","first-page":"109","volume":"70","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. & Wetzels, J. F. Anti-PLA2R antibodies in membranous nephropathy: ready for routine clinical practice? Neth. J. Med. 70, 109\u2013113 (2012).","journal-title":"Neth. J. Med."},{"key":"BFnrneph2013125_CR18","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","volume":"26","author":"E Hoxha","year":"2011","unstructured":"Hoxha, E. et al. An immunofluorescence test for phospholipase A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol. Dial. Transplant. 26, 2526\u20132532 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2215\/CJN.01330209","volume":"4","author":"MA Hladunewich","year":"2009","unstructured":"Hladunewich, M. A., Troyanov, S., Calafati, J. & Cattran, D. C. The natural history of the non-nephrotic membranous nephropathy patient. Clin. J. Am. Soc. Nephrol. 4, 1417\u20131422 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR20","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 3, 1\u2013150 (2013)."},{"key":"BFnrneph2013125_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco, N. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697\u2013704 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.2215\/CJN.04020411","volume":"6","author":"JA van den Brand","year":"2011","unstructured":"van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 2846\u20132853 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR23","first-page":"211","volume":"57","author":"JK Deegens","year":"2005","unstructured":"Deegens, J. K. & Wetzels, J. F. Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy. Minerva Urol. Nefrol. 57, 211\u2013236 (2005).","journal-title":"Minerva Urol. Nefrol."},{"key":"BFnrneph2013125_CR24","doi-asserted-by":"crossref","unstructured":"The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857\u20131863 (1997).","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"BFnrneph2013125_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with diabetes type 2 and nephropathy. N. Engl. J. Med. 345, 681\u2013689 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrneph2013125_CR26","first-page":"91","volume":"7","author":"RT Gansevoort","year":"1992","unstructured":"Gansevoort, R. T., Heeg, J. E., Vriesendorp, R., de, Z. D. & de Jong, P. E. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol. Dial. Transplant. 7 (Suppl. 1), 91\u201396 (1992).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0272-6386(00)70190-9","volume":"35","author":"P Ruggenenti","year":"2000","unstructured":"Ruggenenti, P. et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am. J. Kidney. Dis. 35, 381\u2013391 (2000).","journal-title":"Am. J. Kidney. Dis."},{"key":"BFnrneph2013125_CR28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","volume":"7","author":"S Ambalavanan","year":"1996","unstructured":"Ambalavanan, S., Fauvel, J. P., Sibley, R. K., Myers, B. D. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 7, 290\u2013298 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth, A. C. et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104, 1985\u20131991 (2001).","journal-title":"Circulation"},{"key":"BFnrneph2013125_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","volume":"46","author":"PW du Buf-Vereijken","year":"2005","unstructured":"du Buf-Vereijken, P. W., Branten, A. J. & Wetzels, J. F. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46, 1012\u20131029 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov, S., Wall, C. A., Miller, J. A., Scholey, J. W. & Cattran, D. C. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 66, 1199\u20131205 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1053\/j.ajkd.2003.10.032","volume":"43","author":"P Rutkowski","year":"2004","unstructured":"Rutkowski, P. et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 43, 260\u2013268 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR33","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1046\/j.1523-1755.62.s82.10.x","volume":"82","author":"J Luno","year":"2002","unstructured":"Luno, J. et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int. Suppl. 82, S47\u2013S52 (2002).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2013125_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR35","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181\u20132192 (2011).","journal-title":"Lancet"},{"key":"BFnrneph2013125_CR36","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1093\/ndt\/gfp012","volume":"24","author":"N Sakurai","year":"2009","unstructured":"Sakurai, N. et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 24, 2378\u20132383 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/HJH.0b013e32831997d6","volume":"27","author":"A Hartner","year":"2009","unstructured":"Hartner, A. et al. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. J. Hypertens. 27, 376\u2013385 (2009).","journal-title":"J. Hypertens."},{"key":"BFnrneph2013125_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ndt\/gfn528","volume":"24","author":"FC Cormack-Aboud","year":"2009","unstructured":"Cormack-Aboud, F. C., Brinkkoetter, P. T., Pippin, J. W., Shankland, S. J. & Durvasula, R. V. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol. Dial. Transplant. 24, 404\u2013412 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.2011.312","volume":"81","author":"SJ Barbour","year":"2012","unstructured":"Barbour, S. J. et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 81, 190\u2013195 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2215\/CJN.04250511","volume":"7","author":"S Lionaki","year":"2012","unstructured":"Lionaki, S. et al. Venous thromboembolism in patients with membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 43\u201351 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000186178","volume":"56","author":"N Ueda","year":"1990","unstructured":"Ueda, N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 56, 374\u2013378 (1990).","journal-title":"Nephron"},{"key":"BFnrneph2013125_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ndt\/gfp390","volume":"25","author":"JM Hofstra","year":"2010","unstructured":"Hofstra, J. M. et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol. Dial. Transplant. 25, 129\u2013136 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.1998.v31.pm9428445","volume":"31","author":"LJ Reichert","year":"1998","unstructured":"Reichert, L. J., Koene, R. A. & Wetzels, J. F. Prognostic factors in idiopathic membranous nephropathy. Am. J. Kidney Dis. 31, 1\u201311 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrneph.2012.161","volume":"8","author":"M Praga","year":"2012","unstructured":"Praga, M. & Rojas-Rivera, J. Glomerular disease: predicting outcomes in idiopathic membranous nephropathy. Nat. Rev. Nephrol. 8, 496\u2013498 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2013125_CR45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ki.1992.374","volume":"42","author":"Y Pei","year":"1992","unstructured":"Pei, Y., Cattran, D. & Greenwood, C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 42, 960\u2013966 (1992).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR46","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/ki.1997.127","volume":"51","author":"DC Cattran","year":"1997","unstructured":"Cattran, D. C. et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 51, 901\u2013907 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1681\/ASN.2004040287","volume":"16","author":"AJ Branten","year":"2005","unstructured":"Branten, A. J. et al. Urinary excretion of \u03b22-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J. Am. Soc. Nephrol. 16, 169\u2013174 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR48","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.2215\/CJN.00670112","volume":"7","author":"JA van den Brand","year":"2012","unstructured":"van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 1242\u20131248 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR49","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","volume":"23","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1735\u20131743 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","volume":"83","author":"D Kanigicherla","year":"2013","unstructured":"Kanigicherla, D. et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 83, 940\u2013948 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR51","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck","year":"2011","unstructured":"Beck, L. H. et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543\u20131550 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR52","doi-asserted-by":"crossref","unstructured":"[No authors listed] A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N. Engl. J. Med. 301, 1301\u20131306 (1979).","DOI":"10.1056\/NEJM197912133012401"},{"key":"BFnrneph2013125_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1056\/NEJM198901263200403","volume":"320","author":"DC Cattran","year":"1989","unstructured":"Cattran, D. C. et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. 320, 210\u2013215 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/oxfordjournals.qjmed.a068422","volume":"74","author":"JS Cameron","year":"1990","unstructured":"Cameron, J. S., Healy, M. J. & Adu, D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q. J. Med. 74, 133\u2013156 (1990).","journal-title":"Q. J. Med."},{"key":"BFnrneph2013125_CR55","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli, C. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48, 1600\u20131604 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR56","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha, V. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18, 1899\u20131904 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1523-1755.2002.00124.x","volume":"61","author":"A Torres","year":"2002","unstructured":"Torres, A. et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 61, 219\u2013227 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR58","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","volume":"19","author":"PW du Buf-Vereijken","year":"2004","unstructured":"du Buf-Vereijken, P. W., Branten, A. J., Wetzels, J. F. & Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol. Dial. Transplant. 19, 1142\u20131148 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR59","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/qjmed\/hch059","volume":"97","author":"PW du Buf-Vereijken","year":"2004","unstructured":"du Buf-Vereijken, P. W. et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. Q. J. Med. 97, 353\u2013360 (2004).","journal-title":"Q. J. Med."},{"key":"BFnrneph2013125_CR60","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1093\/ndt\/gfn350","volume":"23","author":"JM Hofstra","year":"2008","unstructured":"Hofstra, J. M. & Wetzels, J. F. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands. Nephrol. Dial. Transplant. 23, 3534\u20133538 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2215\/CJN.11001210","volume":"6","author":"DC Cattran","year":"2011","unstructured":"Cattran, D. C., Reich, H. N., Kim, S. J. & Troyanov, S. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin. J. Am. Soc. Nephrol. 6, 591\u2013598 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744\u2013751 (2013).","journal-title":"Lancet"},{"key":"BFnrneph2013125_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ndt\/gfh719","volume":"20","author":"AJ Branten","year":"2005","unstructured":"Branten, A. J., Vervoort, G. & Wetzels, J. F. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol. Dial. Transplant. 20, 707\u2013711 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","volume":"91","author":"AJ Branten","year":"1998","unstructured":"Branten, A. J., Reichert, L. J., Koene, R. A. & Wetzels, J. F. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q. J. Med. 91, 359\u2013366 (1998).","journal-title":"Q. J. Med."},{"key":"BFnrneph2013125_CR65","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli, C. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9, 444\u2013450 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR66","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/ard.42.4.368","volume":"42","author":"JA Baltus","year":"1983","unstructured":"Baltus, J. A., Boersma, J. W., Hartman, A. P. & Vandenbroucke, J. P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann. Rheum. Dis. 42, 368\u2013373 (1983).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013125_CR67","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard.2003.019125","volume":"63","author":"A Knight","year":"2004","unstructured":"Knight, A., Askling, J., Granath, F., Sparen, P. & Ekbom, A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann. Rheum. Dis. 63, 1307\u20131311 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2013125_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/0003-4819-91-2-221","volume":"91","author":"PH Plotz","year":"1979","unstructured":"Plotz, P. H. et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann. Int. Med. 91, 221\u2013223 (1979).","journal-title":"Ann. Int. Med."},{"key":"BFnrneph2013125_CR69","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou, M. et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100\u2013105 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2013125_CR70","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6","volume":"41","author":"CC Mok","year":"1998","unstructured":"Mok, C. C., Lau, C. S. & Wong, R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831\u2013837 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013125_CR71","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2004.01.008","volume":"43","author":"S Pendse","year":"2004","unstructured":"Pendse, S., Ginsburg, E. & Singh, A. K. Strategies for preservation of ovarian and testicular function after immunosuppression. Am. J. Kidney. Dis. 43, 772\u2013781 (2004).","journal-title":"Am. J. Kidney. Dis."},{"key":"BFnrneph2013125_CR72","first-page":"2129","volume":"29","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis, J. P., Katsifis, G. E., Tzioufas, A. G. & Moutsopoulos, H. M. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J. Rheumatol. 29, 2129\u20132135 (2002).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2013125_CR73","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/j.1939-4640.1995.tb00538.x","volume":"16","author":"ML Meistrich","year":"1995","unstructured":"Meistrich, M. L., Parchuri, N., Wilson, G., Kurdoglu, B. & Kangasniemi, M. Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J. Androl. 16, 334\u2013341 (1995).","journal-title":"J. Androl."},{"key":"BFnrneph2013125_CR74","first-page":"347","volume":"62","author":"JF Wetzels","year":"2004","unstructured":"Wetzels, J. F. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth. J. Med. 62, 347\u2013352 (2004).","journal-title":"Neth. J. Med."},{"key":"BFnrneph2013125_CR75","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103\u20131112 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR76","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmatic autoantibodies. N. Engl. J. Med. 349, 36\u201344 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013125_CR77","unstructured":"Western Canadian Glomerulonephritis Study Group. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can. Med. Assoc. J. 115, 1209\u20131210 (1976)."},{"key":"BFnrneph2013125_CR78","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0272-6386(99)70081-8","volume":"34","author":"M Ahuja","year":"1999","unstructured":"Ahuja, M., Goumenos, D., Shortland, J. R., Gerakis, A. & Brown, C. B. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am. J. Kidney Dis. 34, 521\u2013529 (1999).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR79","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/oxfordjournals.ndt.a027844","volume":"13","author":"JH Brown","year":"1998","unstructured":"Brown, J. H. et al. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol. Dial. Transplant. 13, 443\u2013448 (1998).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR80","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/qjmed\/90.11.699","volume":"90","author":"JM Bone","year":"1997","unstructured":"Bone, J. M., Rustom, R. & Williams, P. S. 'Progressive' versus 'indolent' idiopathic membranous glomerulonephritis. Q. J. Med. 90, 699\u2013706 (1997).","journal-title":"Q. J. Med."},{"key":"BFnrneph2013125_CR81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5414\/CNP65217","volume":"65","author":"DS Goumenos","year":"2006","unstructured":"Goumenos, D. S., Ahuja, M., Davlouros, P., El Nahas, A. M. & Brown, C. B. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin. Nephrol. 65, 317\u2013323 (2006).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2013125_CR82","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","volume":"61","author":"MJ Choi","year":"2002","unstructured":"Choi, M. J. et al. Mycophenolate treatment for primary glomerular disease. Kidney Int. 61, 1098\u20131114 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR83","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","volume":"52","author":"B Dussol","year":"2008","unstructured":"Dussol, B. et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1 year randomized controlled trial. Am. J. Kidney Dis. 52, 699\u2013705 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/ajkd.2000.8968","volume":"36","author":"G Miller","year":"2000","unstructured":"Miller, G., Zimmerman, R. III, Radhakrishnan, J. & Appel, G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J. Kidney Dis. 36, 250\u2013256 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR85","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","volume":"50","author":"AJ Branten","year":"2007","unstructured":"Branten, A. J., du Buf-Vereijken, P. W., Vervloet, M. & Wetzels, J. F. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am. J. Kidney Dis. 50, 248\u2013256 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR86","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","volume":"23","author":"L Senthil Nayagam","year":"2008","unstructured":"Senthil Nayagam, L. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol. Dial.Transplant. 23, 1926\u20131930 (2008).","journal-title":"Nephrol. Dial.Transplant."},{"key":"BFnrneph2013125_CR87","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","volume":"12","author":"TM Chan","year":"2007","unstructured":"Chan, T. M. et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 12, 576\u2013581 (2007).","journal-title":"Nephrology"},{"issue":"Suppl. 1","key":"BFnrneph2013125_CR88","first-page":"80","volume":"7","author":"A Meyrier","year":"1992","unstructured":"Meyrier, A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol. Dial. Transplant. 7 (Suppl. 1), 80\u201384 (1992).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR89","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931\u2013938 (2008).","journal-title":"Nat. Med."},{"key":"BFnrneph2013125_CR90","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.1995.161","volume":"47","author":"DC Cattran","year":"1995","unstructured":"Cattran, D. C. et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 47, 1130\u20131135 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR91","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59, 1484\u20131490 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR92","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1093\/ndt\/gfl360","volume":"21","author":"E Alexopoulos","year":"2006","unstructured":"Alexopoulos, E., Papagianni, A., Tsamelashvili, M., Leontsini, M. & Memmos, D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol. Dial. Transplant. 21, 3127\u20133132 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR93","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga, M., Barrio, V., Ju\u00e1rez, G. F., Lu\u00f1o, J. & Grupo Espa\u00f1ol de Estudio de la Nefropat\u00eda Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924\u2013930 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR94","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1440-1797.2010.01301.x","volume":"15","author":"P Kalliakmani","year":"2010","unstructured":"Kalliakmani, P., Koutroulia, E., Sotsiou, F., Vlachojannis, J. G. & Goumenos, D. S. Benefit and cost from the long-term use of cyclosporine A in idiopathic membranous nephropathy. Nephrology 15, 762\u2013767 (2010).","journal-title":"Nephrology"},{"key":"BFnrneph2013125_CR95","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923\u2013924 (2002).","journal-title":"Lancet"},{"key":"BFnrneph2013125_CR96","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza, F. C. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117\u2013125 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR97","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza, F. C. et al. Rituximab therapy in idiopathic membranous nephropathy: a 2 year study. Clin. J. Am. Soc. Nephrol. 5, 2188\u20132198 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR98","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2215\/CJN.01180307","volume":"2","author":"P Cravedi","year":"2007","unstructured":"Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C. & Remuzzi, G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2, 932\u2013937 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR99","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2215\/CJN.01080905","volume":"1","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738\u2013748 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR100","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti, P. et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416\u20131425 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrneph2013125_CR102","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra, A. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 4, 1083\u20131088 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR103","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","volume":"56","author":"AL Berg","year":"1999","unstructured":"Berg, A. L., Nilsson-Ehle, P. & Arnadottir, M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 56, 1534\u20131543 (1999).","journal-title":"Kidney Int."},{"key":"BFnrneph2013125_CR104","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","volume":"19","author":"AL Berg","year":"2004","unstructured":"Berg, A. L. & Arnadottir, M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol. Dial. Transplant. 19, 1305\u20131307 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR105","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1681\/ASN.2009101025","volume":"21","author":"AM Lindskog","year":"2010","unstructured":"Lindskog, A. M. et al. Melanocortin 1 receptor agonists reduce proteinuria. J. Am. Soc. Nephrol. 21, 1290\u20131298 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR106","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","volume":"47","author":"C Ponticelli","year":"2006","unstructured":"Ponticelli, C. et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47, 233\u2013240 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013125_CR107","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DDDT.S17521","volume":"5","author":"AS Bomback","year":"2011","unstructured":"Bomback, A. S. et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Devel. Ther. 5, 147\u2013153 (2011).","journal-title":"Drug Des. Devel. Ther."},{"key":"BFnrneph2013125_CR108","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000339287","volume":"36","author":"AS Bomback","year":"2012","unstructured":"Bomback, A. S. et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol. 36, 58\u201367 (2012).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2013125_CR109","first-page":"FR-OR125","volume":"23","author":"M Hladunewich","year":"2012","unstructured":"Hladunewich, M. et al. A pilot study to determine dose, effectiveness and depletion of anti-PLA2R antibodies of adrenocorticotrophic hormone (ACTH Acthar\u00ae Gel) in subjects with nephrotic syndrome and idiopathic membranous nephropathy [abstract]. J. Am Soc. Nephrol. 23, FR-OR125 (2012).","journal-title":"J. Am Soc. Nephrol."},{"key":"BFnrneph2013125_CR110","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/ndt\/gfi219","volume":"21","author":"PW du Buf-Vereijken","year":"2006","unstructured":"du Buf-Vereijken, P. W. & Wetzels, J. F. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. Nephrol. Dial. Transplant. 21, 389\u2013396 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR111","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ndt\/gfs379","volume":"28","author":"MV Irazabal","year":"2013","unstructured":"Irazabal, M. V. et al. Low and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol. Dial. Transplant. 28, 137\u2013146 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR112","unstructured":"ERA-EDTA Immunonephrology Working Group. Ongoing Projects [online] , (2012)."},{"key":"BFnrneph2013125_CR113","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328\u20132337 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2013125_CR114","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrneph2013125_CR115","doi-asserted-by":"publisher","unstructured":"Fervenza, F. C., Glassock, R. J. & Bleyer, A. J. American Society of Nephrology Quiz and Questionnaire 2012: Glomerulonephritis. Clin. J. Am. Soc. Nephrol. http:\/\/dx.doi.org\/10.2215\/CJN.00440113 .","DOI":"10.2215\/CJN.00440113"},{"key":"BFnrneph2013125_CR116","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2215\/CJN.02170312","volume":"27","author":"C Murtas","year":"2012","unstructured":"Murtas, C. et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 27, 1394\u20131400 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013125_CR117","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1093\/ndt\/gfm366","volume":"22","author":"J Ballarin","year":"2007","unstructured":"Ballarin, J. et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol. Dial. Transplant. 22, 3196\u20133201 (2007).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013125_CR118","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000187219","volume":"63","author":"G Rostoker","year":"1993","unstructured":"Rostoker, G. et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63, 335\u2013341 (1993).","journal-title":"Nephron"},{"key":"BFnrneph2013125_CR119","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5414\/CNP61017","volume":"61","author":"DS Goumenos","year":"2004","unstructured":"Goumenos, D. S., Kalliakmani, P., Tsakas, S., Sotsiou, F. & Vlachojannis, J. G. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin. Nephrol. 61, 17\u201324 (2004).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2013125_CR120","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000101367","volume":"27","author":"DS Goumenos","year":"2007","unstructured":"Goumenos, D. S. et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am. J. Nephrol. 27, 226\u2013231 (2007).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2013125_CR121","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen, M. et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am. J. Med. Sci. 339, 233\u2013238 (2010).","journal-title":"Am. J. Med. Sci."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:51:02Z","timestamp":1715619062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,2]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFnrneph2013125"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2013.125","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,2]]}}}